• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 23, 2017

View Archived Issues

Rexgenero rises to the critical limb ischemia challenge

BARCELONA, Spain – What may well be Europe's least known cell therapy company has just begun a phase III trial of its lead program in a notoriously challenging indication. Rexgenero Ltd. began recruiting diabetic patients with critical limb ischemia (CLI) last week, CEO Joe Dupere told BioWorld Today. He expects the first patient to receive treatment by the end of this month. Read More

Beyond the checkpoint: Pionyr advancing I-O via precision tuning

The advent of checkpoint inhibitors yielded a big win for the burgeoning immuno-oncology space, supercharging activated T cells to attack cancer cells, and the success with drugs targeting CTLA-4 and PD-1 has translated into efforts chasing other checkpoint mechanisms, all in the hopes of expanding the stunning results into broader patient populations. Read More

PDUFA VI a must-pass enhancement for 21st Century Cures

No political tantrums upstaged the importance of passing PDUFA VI in a timely manner when a House subcommittee met Wednesday to discuss the user fee agreement that the FDA, industry and patient groups have negotiated over the past two years. Read More

Poor communication practices drive up drug costs in Asia

SINGAPORE – Asia's rapidly developing health care ecosystem should ease market access for pharmaceutical companies and drug access for patients, but communication and transparency remain a key challenge hindering development. Unless all stakeholders in the sector come together, drug costs will remain high, industry experts said at the BioPharma Asia Convention here. Read More

Financings

Vital Therapies Inc., of San Diego, which is developing Elad, a cell-based therapy targeting the treatment of acute forms of liver failure, said it priced an underwritten public offering of 8.75 million newly issued shares of its common stock at $4 per share for gross proceeds of approximately $35 million. Read More

Other news to note

Opko Pharmaceuticals LLC, of Miami, gained FDA orphan status for oligonucleotide-based Antagonat (CUR-1916) for the treatment of Dravet syndrome. The Antagonat technology, part of Curna Pharmaceuticals, acquired by Opko in 2011 for $10 million. It was further developed in Opko's Miami research laboratories. (See BioWorld Today, Feb. 2, 2011.) Read More

In the clinic

Aveo Oncology Inc., of Cambridge, Mass., said the first patient has been dosed in the phase I/II Aveo-sponsored TiNivo trial evaluating tivozanib in combination with New York-based Bristol-Myers Squibb Co.'s anti-PD-1 therapy, Opdivo (nivolumab), in advanced renal cell carcinoma. Tivozanib is an oral, once-daily, vascular endothelial growth factor tyrosine kinase inhibitor. Read More

Appointments and advancements

GW Pharmaceuticals plc, of London, appointed Scott Giacobello chief financial officer, and Adam George managing director – UK. Giacobello will be based at the company's U.S. headquarters in Carlsbad, Calif. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 25, 2025.
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Gold dollar sign inside gold cog

    Revmed goes global with $2B in capital for RAS(ON) inhibitors

    BioWorld
    Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe